Nuveen’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $33.3M | Sell |
2,300,567
-2,327,658
| -50% | -$33.4M | 0.01% | 847 |
|
|
2025
Q4 | $65.9M | Buy |
4,628,225
+5,828
| +0.1% | +$57.3K | 0.02% | 528 |
|
|
2025
Q3 | $36.4M | Buy |
4,622,397
+990,596
| +27% | +$7.05M | 0.01% | 786 |
|
|
2025
Q2 | $20.8M | Buy |
3,631,801
+109,584
| +3% | +$707K | 0.01% | 1081 |
|
|
2025
Q1 | $28.7M | Sell |
3,522,217
-285,203
| -7% | -$2.64M | 0.01% | 905 |
|
|
2024
Q4 | $35.9M | Buy |
3,807,420
+159,139
| +4% | +$1.65M | 0.01% | 821 |
|
|
2024
Q3 | $39M | Buy |
3,648,281
+1,748,774
| +92% | +$19M | 0.01% | 786 |
|
|
2024
Q2 | $18.8M | Buy |
1,899,507
+751,963
| +66% | +$7.72M | 0.01% | 1167 |
|
|
2024
Q1 | $13.5M | Sell |
1,147,544
-255,028
| -18% | -$3.26M | ﹤0.01% | 1415 |
|
|
2023
Q4 | $19.9M | Buy |
1,402,572
+161,746
| +13% | +$1.84M | 0.01% | 1163 |
|
|
2023
Q3 | $15.1M | Buy |
1,240,826
+426,144
| +52% | +$5.5M | 0.01% | 1221 |
|
|
2023
Q2 | $10.2M | Buy |
814,682
+4,476
| +0.6% | +$53.1K | ﹤0.01% | 1498 |
|
|
2023
Q1 | $8.99M | Sell |
810,206
-165,086
| -17% | -$2.03M | ﹤0.01% | 1553 |
|
|
2022
Q4 | $11.9M | Sell |
975,292
-155,443
| -14% | -$1.75M | ﹤0.01% | 1378 |
|
|
2022
Q3 | $11.8M | Sell |
1,130,735
-131,828
| -10% | -$1.47M | ﹤0.01% | 1376 |
|
|
2022
Q2 | $13.6M | Buy |
1,262,563
+169,893
| +16% | +$1.4M | 0.01% | 1322 |
|
|
2022
Q1 | $10.5M | Sell |
1,092,670
-375,481
| -26% | -$3.52M | ﹤0.01% | 1613 |
|
|
2021
Q4 | $15M | Sell |
1,468,151
-157,321
| -10% | -$1.75M | ﹤0.01% | 1425 |
|
|
2021
Q3 | $17.9M | Sell |
1,625,472
-310,165
| -16% | -$3.17M | 0.01% | 1346 |
|
|
2021
Q2 | $18.7M | Sell |
1,935,637
-346,769
| -15% | -$3.38M | 0.01% | 1423 |
|
|
2021
Q1 | $22.6M | Sell |
2,282,406
-378,628
| -14% | -$5.86M | 0.01% | 1228 |
|
|
2020
Q4 | $61.4M | Sell |
2,661,034
-36,009
| -1% | -$736K | 0.02% | 596 |
|
|
2020
Q3 | $38.1M | Sell |
2,697,043
-205,939
| -7% | -$3M | 0.01% | 687 |
|
|
2020
Q2 | $43.8M | Sell |
2,902,982
-130,178
| -4% | -$1.59M | 0.02% | 598 |
|
|
2020
Q1 | $28M | Sell |
3,033,160
-1,121,611
| -27% | -$10.7M | 0.01% | 719 |
|
|
2019
Q4 | $40.5M | Buy |
4,154,771
+2,000,176
| +93% | +$18.3M | 0.02% | 780 |
|
|
2019
Q3 | $17.3M | Sell |
2,154,595
-797,926
| -27% | -$8.66M | 0.01% | 1218 |
|
|
2019
Q2 | $36.8M | Buy |
+2,952,521
| New | +$37.5M | 0.01% | 837 |
|
|
2017
Q1 | – | Sell |
-10,341
| Closed | -$51K | – | 1406 |
|
|
2016
Q4 | $51K | Buy |
+10,341
| New | +$71.6K | ﹤0.01% | 1489 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Nuveen's FOLD Position: Q1 2026 in Review
Nuveen reduced its Amicus Therapeutics (FOLD) stake by 50% in Q1 2026, selling an estimated $33.4M and leaving 2,300,567 shares worth $33.3M. The position accounts for 0.01% of the portfolio, ranked #847.
Nuveen first reported a position in FOLD in Q4 2016 and has held it in 29 quarters since. The position peaked at $65.9M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Nuveen held 2,300,567 shares of Amicus Therapeutics worth $33.3M as of Q1 2026.
- Nuveen sold 2,327,658 Amicus Therapeutics shares in Q1 2026, an estimated $33.4M.
- Amicus Therapeutics made up 0.01% of Nuveen's portfolio in Q1 2026, its #847 holding.
- Nuveen first reported a position in Amicus Therapeutics in Q4 2016 and has held it in 29 quarters since.
- Nuveen's Amicus Therapeutics position peaked at $65.9M in Q4 2025.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.